Sign up to save your podcasts
Or
Share The Role of HER3 Expression in Advanced Solid Tumors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Role of HER3 Expression in Advanced Solid Tumors
CME credits: 0.50
Valid until: 19-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-her3-expression-in-advanced-solid-tumors/12956/
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 19-08-2023
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-her3-expression-in-advanced-solid-tumors/12956/
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
=